{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-25-000091","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.321644+00:00","generated_at":"2026-05-16T23:34:50.508976+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Neurogene doses first participant in Embolden registrational trial of NGN-401 for Rett syndrome","bullets":["First participant dosed in single-arm, open-label, baseline-controlled registrational trial of NGN-401 gene therapy for Rett syndrome.","Trial targets 20 females ages 3+; enrollment expected to complete in 3-6 months.","12 of 13 clinical sites initiated; trial designed to support future BLA submission.","Company to present Phase 1/2 interim data at Stifel Healthcare Conference on November 12, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-25-000091","json":"https://secwatch.observer/filing/0001404644-25-000091.json","markdown":"https://secwatch.observer/filing/0001404644-25-000091.md","text":"https://secwatch.observer/filing/0001404644-25-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000091/0001404644-25-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000091/ngne-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:34:50.508976+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}